A therapeutic strategy for beta thal and sickle cell anemia based on the increase in delta-globin may have the advantage over reactivating gamma-globin that the expression of the delta-globin gene is pan-cellular, while that of the gamma-globin gene is heterocellular (3). This evidence concerns the gene HBA1 and sickle cell disease.